Christopher Weyrer, MD, PhD
Santa Monica, California, United States
2K followers
500+ connections
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
-
-
-
-
-
-
-
Languages
-
Deutsch
Native or bilingual proficiency
-
English
Native or bilingual proficiency
-
Français
Limited working proficiency
-
Español
Limited working proficiency
-
Latin
Elementary proficiency
Organizations
-
GSAS Harvard Biotechnology Club
-
- PresentJournal Clubs, Workshops, Events & Networking
-
Harvard Graduate Consulting Club
-
- PresentCase studies & Consulting Competitions, Workshops, Networking, Training and Events
-
Harvard Innovation-Lab (i-Lab), TECH & Harvard Business School
-
- PresentTraining in Entrepreneurship, Start-Ups and Venture Capitalism
-
CamFM - BBC supported radio station Cambridge, UK
Member, Host, Presenter
- Present -
Oxbridge Biotech Roundtable
-
- PresentTraining and Events in Entrepreneurship, Venture Capitalism, Consulting and Biotech
-
Vibetime Recordings - www.vibetime.at
Co-Founder
- PresentEvent Managment, Music Production, DJing, Marketing & Equipment Leisure
-
Cambridge Coding Academy
-
-Programming Workshops
Other similar profiles
Explore more posts
-
Martin Borch Jensen
Morten Scheibye-Knudsen & Alex Zhavoronkov's ARDD is a great conference in part because it spans basic research through drug development. Thinking about how research turns into medicines is critical for the longevity field. By default, a whole body mutation of a transcription factor is not going to be a drug. And without aligning with pharma interests, funding trials will be tricky. So Gordian Biotechnology is asking people in longevity to write short (100-500 word) essays on how to bridge aging research and drug development, for a chance at a free ARDD ticket.
1 Comment -
Michael Sidler
Excited to welcome Valink Therapeutics to the redalpine family! Valink is reimagining targeted #cancer therapies with a software x science approach: programmable biology meets data-driven and AI-enabled discovery. Founders Arne Scheu and Irsyad Khairil impressed us from the start with sharp strategy and fast execution. Their V-GATE™ platform systematically engineers bispecific #ADCs with true target synergy — unlocking new levels of efficacy and safety. We’re proud to lead their $11.8M round, joined by LongeVC, Oxford Science Enterprises, and returning backers RV Invest, p53 Invest, and Hoxton Ventures. With fresh capital and a new U.S. office in Cambridge, MA, Valink is set to scale. Let’s build the future of precision therapeutics! 🚀 🚀 🚀
5 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content